Metropolis Launches Blood-Based Test for Early Alzheimer’s Screening

The company stated that the test demonstrates diagnostic accuracy exceeding 90% and aligns strongly with amyloid PET imaging, a key standard in Alzheimer’s diagnostics.

Metropolis Healthcare has launched an advanced blood-based test designed to support earlier detection of Alzheimer’s disease (AD) and improve clinical decision-making, particularly in individuals over the age of 50.

Distinct neuropathological changes characterize Alzheimer’s disease, and its diagnosis typically relies on a combination of clinical evaluation, neuroimaging, and validated biomarkers.

However, early-stage Alzheimer’s remains underdiagnosed, as symptoms such as mild cognitive decline are often overlooked or attributed to normal aging. Early identification of individuals at higher risk can help enable timely interventions, closer monitoring, and more structured disease management.

The newly introduced test enables screening through a simple blood sample, offering a minimally invasive alternative to traditional diagnostic methods such as positron emission tomography (PET) scans or cerebrospinal fluid (CSF) testing. The company stated that the test demonstrates diagnostic accuracy exceeding 90% and aligns strongly with amyloid PET imaging, a key standard in Alzheimer’s diagnostics.

The test is positioned as an initial step in the clinical evaluation pathway. Based on the results, clinicians can determine whether patients require further confirmatory testing, including PET imaging or CSF analysis. This approach is in line with 2025 clinical practice recommendations from the Alzheimer’s Association, which support the use of blood-based biomarkers in appropriate settings.

Surendran Chemmenkotil, Managing Director, Metropolis Healthcare, said, “As India’s population ages, timely and accessible diagnostics for neurodegenerative diseases are becoming increasingly important. We are expanding access to advanced testing that enables earlier evaluation and better clinical decisions. This test serves as a critical first step in the diagnostic pathway, helping identify patients who need further evaluation while reducing unnecessary procedures.”

Dr Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare Limited, added, “In Alzheimer’s care, blood-based biomarkers can provide an additional layer of objective evidence for early-stage clinical decision making. A blood-based biomarker test with a sensitivity of 90% or higher is recommended as a triaging tool, where a negative result can reliably rule out Alzheimer’s pathology. It is important to note that not all blood-based assays meet the rigorous standards set forth, hence ensuring optimum quality standards and test validation protocols is of utmost importance. The results should always be interpreted in the context of a comprehensive clinical evaluation.”

Stay tuned for more such updates on Digital Health News